Serum Institute of India (SII) mentioned on Friday that manufacturing of the primary batch of Covovax, the Covid-19 vaccine developed by US-based Novavax, has began in Pune.
The Centre expects 200 million doses of Covovax to be out there between August and December. India will enable entry of this vaccine as soon as the USFDA approves it.
In a tweet, on its official deal with, the corporate mentioned, “A brand new milestone has been reached; this week we started our first batch of Covovax at our facility, right here in Pune.”
The corporate has been stockpiling Covovax doses for a while now. This was in small volumes, SII clarified. The goal month-to-month manufacturing of Covovax is 50 million. The corporate is predicted to scale as much as that stage by the September quarter, declare sources.
In the meantime, SII has additionally indicated that it plans to start out scientific trials on kids for Covovax in July.
Novavax had mentioned this month that it obtained promising outcomes from its PREVENT-19 part 3 trials within the US and Mexico, with an total efficacy of 90.4 per cent.
The vaccine candidate NVX-CoV2373 has proven 100 per cent safety towards reasonable and extreme illness in addition to 90.4 per cent efficacy total. It additionally met the first endpoint within the PREVENT-19 part 3 trials, the corporate had mentioned in an announcement.
Novavax will file regulatory authorisations within the third quarter (of the calendar yr), it added. Upon regulatory approvals, the corporate mentioned it’s on observe to succeed in manufacturing capability of 100 million doses a month by the tip of the third quarter and 150 million doses per 30 days by the fourth quarter of 2021.
SII chief government officer (CEO) Adar Poonawalla had earlier mentioned that scarcity of uncooked materials provides from the US had affected the size up plan for Covovax.